Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1

Interventions

Specimen Handling 199Magnetic Resonance Spectroscopy 150Biopsy 121pembrolizumab 94Carboplatin 85Cisplatin 77Nivolumab 74Cyclophosphamide 70Paclitaxel 65Gemcitabine 53Radiotherapy 49Bevacizumab 45durvalumab 41Dexamethasone 39Fluorouracil 35Doxorubicin 35Capecitabine 35venetoclax 34olaparib 33atezolizumab 33Pemetrexed 33Injections 32Rituximab 31Oxaliplatin 31Radiation 29Prednisone 29Etoposide 29fludarabine 28Lenalidomide 28cemiplimab 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × ibritumomab tiuxetan × 30 days × Clear all
NCT00690560 2026-05-22

Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma

Centre Antoine Lacassagne

Phase 2 Completed
30 enrolled 11 charts
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡